metricas
covid
Buscar en
Gastroenterología y Hepatología
Toda la web
Inicio Gastroenterología y Hepatología Vedolizumab-induced cholestatic liver injury
Journal Information

Statistics

Follow this link to access the full text of the article

Letter to the Editor
Vedolizumab-induced cholestatic liver injury
Lesión hepática colestásica inducida por vedolizumab
María Rojas-Feriab,
Corresponding author
mrojasferia@gmail.com

Corresponding author.
, Miguel Rodríguez-Fernándeza, Manuel Castro-Fernándezb, Emilio Suárez-Garcíab
a Department of Internal Medicine, Valme University Hospital, UGC Internal Medicine, Servicio Andaluz de Salud, Seville E-41014, Spain
b Department of Digestive Diseases, Valme University Hospital, UGC Digestive Diseases, Servicio Andaluz de Salud, Seville E-41014, Spain
Read
763
Times
was read the article
191
Total PDF
572
Total HTML
Share statistics
 array:24 [
  "pii" => "S0210570520304428"
  "issn" => "02105705"
  "doi" => "10.1016/j.gastrohep.2020.11.009"
  "estado" => "S300"
  "fechaPublicacion" => "2022-01-01"
  "aid" => "1717"
  "copyright" => "Elsevier España, S.L.U.. All rights reserved"
  "copyrightAnyo" => "2020"
  "documento" => "simple-article"
  "crossmark" => 1
  "subdocumento" => "cor"
  "cita" => "Gastroenterol Hepatol. 2022;45:64-5"
  "abierto" => array:3 [
    "ES" => false
    "ES2" => false
    "LATM" => false
  ]
  "gratuito" => false
  "lecturas" => array:1 [
    "total" => 0
  ]
  "Traduccion" => array:1 [
    "en" => array:19 [
      "pii" => "S2444382422000116"
      "issn" => "24443824"
      "doi" => "10.1016/j.gastre.2020.11.010"
      "estado" => "S300"
      "fechaPublicacion" => "2022-01-01"
      "aid" => "1717"
      "copyright" => "Elsevier España, S.L.U."
      "documento" => "simple-article"
      "crossmark" => 1
      "subdocumento" => "cor"
      "cita" => "Gastroenterol Hepatol. 2022;45:64-5"
      "abierto" => array:3 [
        "ES" => false
        "ES2" => false
        "LATM" => false
      ]
      "gratuito" => false
      "lecturas" => array:1 [
        "total" => 0
      ]
      "en" => array:11 [
        "idiomaDefecto" => true
        "cabecera" => "<span class="elsevierStyleTextfn">Letter to the Editor</span>"
        "titulo" => "Vedolizumab-induced cholestatic liver injury"
        "tienePdf" => "en"
        "tieneTextoCompleto" => "en"
        "paginas" => array:1 [
          0 => array:2 [
            "paginaInicial" => "64"
            "paginaFinal" => "65"
          ]
        ]
        "titulosAlternativos" => array:1 [
          "es" => array:1 [
            "titulo" => "Lesi&#243;n hep&#225;tica colest&#225;sica inducida por vedolizumab"
          ]
        ]
        "contieneTextoCompleto" => array:1 [
          "en" => true
        ]
        "contienePdf" => array:1 [
          "en" => true
        ]
        "resumenGrafico" => array:2 [
          "original" => 0
          "multimedia" => array:7 [
            "identificador" => "fig0005"
            "etiqueta" => "Figure 1"
            "tipo" => "MULTIMEDIAFIGURA"
            "mostrarFloat" => true
            "mostrarDisplay" => false
            "figura" => array:1 [
              0 => array:4 [
                "imagen" => "gr1.jpeg"
                "Alto" => 1684
                "Ancho" => 2508
                "Tamanyo" => 150194
              ]
            ]
            "descripcion" => array:1 [
              "en" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">Temporal evolution of liver-associated enzymes in the course of VDZ treatment&#46;</p>"
            ]
          ]
        ]
        "autores" => array:1 [
          0 => array:2 [
            "autoresLista" => "Mar&#237;a Rojas-Feria, Miguel Rodr&#237;guez-Fern&#225;ndez, Manuel Castro-Fern&#225;ndez, Emilio Su&#225;rez-Garc&#237;a"
            "autores" => array:4 [
              0 => array:2 [
                "nombre" => "Mar&#237;a"
                "apellidos" => "Rojas-Feria"
              ]
              1 => array:2 [
                "nombre" => "Miguel"
                "apellidos" => "Rodr&#237;guez-Fern&#225;ndez"
              ]
              2 => array:2 [
                "nombre" => "Manuel"
                "apellidos" => "Castro-Fern&#225;ndez"
              ]
              3 => array:2 [
                "nombre" => "Emilio"
                "apellidos" => "Su&#225;rez-Garc&#237;a"
              ]
            ]
          ]
        ]
      ]
      "idiomaDefecto" => "en"
      "Traduccion" => array:1 [
        "en" => array:9 [
          "pii" => "S0210570520304428"
          "doi" => "10.1016/j.gastrohep.2020.11.009"
          "estado" => "S300"
          "subdocumento" => ""
          "abierto" => array:3 [
            "ES" => false
            "ES2" => false
            "LATM" => false
          ]
          "gratuito" => false
          "lecturas" => array:1 [
            "total" => 0
          ]
          "idiomaDefecto" => "en"
          "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0210570520304428?idApp=UINPBA00004N"
        ]
      ]
      "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2444382422000116?idApp=UINPBA00004N"
      "url" => "/24443824/0000004500000001/v1_202202060539/S2444382422000116/v1_202202060539/en/main.assets"
    ]
  ]
  "itemSiguiente" => array:19 [
    "pii" => "S0210570521001436"
    "issn" => "02105705"
    "doi" => "10.1016/j.gastrohep.2021.02.022"
    "estado" => "S300"
    "fechaPublicacion" => "2022-01-01"
    "aid" => "1796"
    "copyright" => "Elsevier Espa&#241;a&#44; S&#46;L&#46;U&#46;"
    "documento" => "article"
    "crossmark" => 1
    "subdocumento" => "rev"
    "cita" => "Gastroenterol Hepatol. 2022;45:66-76"
    "abierto" => array:3 [
      "ES" => false
      "ES2" => false
      "LATM" => false
    ]
    "gratuito" => false
    "lecturas" => array:1 [
      "total" => 0
    ]
    "es" => array:13 [
      "idiomaDefecto" => true
      "cabecera" => "<span class="elsevierStyleTextfn">Revisi&#243;n</span>"
      "titulo" => "S&#237;ndrome de intestino irritable en la enfermedad inflamatoria intestinal&#46; &#191;Sinergia en las alteraciones del eje cerebro-intestino&#63;"
      "tienePdf" => "es"
      "tieneTextoCompleto" => "es"
      "tieneResumen" => array:2 [
        0 => "es"
        1 => "en"
      ]
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "66"
          "paginaFinal" => "76"
        ]
      ]
      "titulosAlternativos" => array:1 [
        "en" => array:1 [
          "titulo" => "Irritable bowel syndrome in inflammatory bowel disease&#46; Synergy in alterations of the gut-brain axis&#63;"
        ]
      ]
      "contieneResumen" => array:2 [
        "es" => true
        "en" => true
      ]
      "contieneTextoCompleto" => array:1 [
        "es" => true
      ]
      "contienePdf" => array:1 [
        "es" => true
      ]
      "resumenGrafico" => array:2 [
        "original" => 0
        "multimedia" => array:7 [
          "identificador" => "fig0005"
          "etiqueta" => "Figura 1"
          "tipo" => "MULTIMEDIAFIGURA"
          "mostrarFloat" => true
          "mostrarDisplay" => false
          "figura" => array:1 [
            0 => array:4 [
              "imagen" => "gr1.jpeg"
              "Alto" => 2252
              "Ancho" => 3175
              "Tamanyo" => 352173
            ]
          ]
          "descripcion" => array:1 [
            "es" => "<p id="spar0015" class="elsevierStyleSimplePara elsevierViewall">Mecanismos implicados en la superposici&#243;n de enfermedad inflamatoria intestinal-s&#237;ndrome de intestino irritable&#46;</p>"
          ]
        ]
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "Edith P&#233;rez de Arce, Rodrigo Quera, Caroll J&#46; Beltr&#225;n, Ana Mar&#237;a Madrid, Pilar Nos"
          "autores" => array:5 [
            0 => array:2 [
              "nombre" => "Edith"
              "apellidos" => "P&#233;rez de Arce"
            ]
            1 => array:2 [
              "nombre" => "Rodrigo"
              "apellidos" => "Quera"
            ]
            2 => array:2 [
              "nombre" => "Caroll J&#46;"
              "apellidos" => "Beltr&#225;n"
            ]
            3 => array:2 [
              "nombre" => "Ana Mar&#237;a"
              "apellidos" => "Madrid"
            ]
            4 => array:2 [
              "nombre" => "Pilar"
              "apellidos" => "Nos"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "es"
    "Traduccion" => array:1 [
      "en" => array:9 [
        "pii" => "S2444382421002327"
        "doi" => "10.1016/j.gastre.2021.02.007"
        "estado" => "S300"
        "subdocumento" => ""
        "abierto" => array:3 [
          "ES" => false
          "ES2" => false
          "LATM" => false
        ]
        "gratuito" => false
        "lecturas" => array:1 [
          "total" => 0
        ]
        "idiomaDefecto" => "en"
        "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2444382421002327?idApp=UINPBA00004N"
      ]
    ]
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0210570521001436?idApp=UINPBA00004N"
    "url" => "/02105705/0000004500000001/v2_202201010823/S0210570521001436/v2_202201010823/es/main.assets"
  ]
  "itemAnterior" => array:19 [
    "pii" => "S0210570520303782"
    "issn" => "02105705"
    "doi" => "10.1016/j.gastrohep.2020.09.003"
    "estado" => "S300"
    "fechaPublicacion" => "2022-01-01"
    "aid" => "1673"
    "copyright" => "Elsevier Espa&#241;a&#44; S&#46;L&#46;U&#46;"
    "documento" => "article"
    "crossmark" => 1
    "subdocumento" => "sco"
    "cita" => "Gastroenterol Hepatol. 2022;45:62-3"
    "abierto" => array:3 [
      "ES" => false
      "ES2" => false
      "LATM" => false
    ]
    "gratuito" => false
    "lecturas" => array:1 [
      "total" => 0
    ]
    "es" => array:11 [
      "idiomaDefecto" => true
      "cabecera" => "<span class="elsevierStyleTextfn">Imagen del mes</span>"
      "titulo" => "Lesiones cut&#225;neas con f&#225;rmacos biol&#243;gicos en la enfermedad inflamatoria intestinal&#58; m&#225;s all&#225; de la psoriasis"
      "tienePdf" => "es"
      "tieneTextoCompleto" => "es"
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "62"
          "paginaFinal" => "63"
        ]
      ]
      "titulosAlternativos" => array:1 [
        "en" => array:1 [
          "titulo" => "Skin injuries associated with biological therapy in inflammatory bowel disease&#58; beyond psoriasis"
        ]
      ]
      "contieneTextoCompleto" => array:1 [
        "es" => true
      ]
      "contienePdf" => array:1 [
        "es" => true
      ]
      "resumenGrafico" => array:2 [
        "original" => 0
        "multimedia" => array:7 [
          "identificador" => "fig0005"
          "etiqueta" => "Figura 1"
          "tipo" => "MULTIMEDIAFIGURA"
          "mostrarFloat" => true
          "mostrarDisplay" => false
          "figura" => array:1 [
            0 => array:4 [
              "imagen" => "gr1.jpeg"
              "Alto" => 996
              "Ancho" => 750
              "Tamanyo" => 86001
            ]
          ]
          "descripcion" => array:1 [
            "es" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">Afectaci&#243;n palmo-plantar en forma de p&#225;pulas eritematosas con un collarete escamoso hiperquerat&#243;sico pudiendo adoptar un aspecto psoriasiforme&#46; Lesi&#243;n de mayor tama&#241;o en forma de hiperqueratosis localizada &#40;flecha negra&#41;&#46;</p>"
          ]
        ]
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "Alejandro M&#237;nguez Sabater, Sara Mart&#237;nez Delgado, Pablo Ladr&#243;n Abia, Guillermo Bastida"
          "autores" => array:4 [
            0 => array:2 [
              "nombre" => "Alejandro"
              "apellidos" => "M&#237;nguez Sabater"
            ]
            1 => array:2 [
              "nombre" => "Sara"
              "apellidos" => "Mart&#237;nez Delgado"
            ]
            2 => array:2 [
              "nombre" => "Pablo"
              "apellidos" => "Ladr&#243;n Abia"
            ]
            3 => array:2 [
              "nombre" => "Guillermo"
              "apellidos" => "Bastida"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "es"
    "Traduccion" => array:1 [
      "en" => array:9 [
        "pii" => "S2444382421002376"
        "doi" => "10.1016/j.gastre.2020.09.011"
        "estado" => "S300"
        "subdocumento" => ""
        "abierto" => array:3 [
          "ES" => false
          "ES2" => false
          "LATM" => false
        ]
        "gratuito" => false
        "lecturas" => array:1 [
          "total" => 0
        ]
        "idiomaDefecto" => "en"
        "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2444382421002376?idApp=UINPBA00004N"
      ]
    ]
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0210570520303782?idApp=UINPBA00004N"
    "url" => "/02105705/0000004500000001/v2_202201010823/S0210570520303782/v2_202201010823/es/main.assets"
  ]
  "en" => array:15 [
    "idiomaDefecto" => true
    "cabecera" => "<span class="elsevierStyleTextfn">Letter to the Editor</span>"
    "titulo" => "Vedolizumab-induced cholestatic liver injury"
    "tieneTextoCompleto" => true
    "saludo" => "Dear Editor&#44;"
    "paginas" => array:1 [
      0 => array:2 [
        "paginaInicial" => "64"
        "paginaFinal" => "65"
      ]
    ]
    "autores" => array:1 [
      0 => array:4 [
        "autoresLista" => "Mar&#237;a Rojas-Feria, Miguel Rodr&#237;guez-Fern&#225;ndez, Manuel Castro-Fern&#225;ndez, Emilio Su&#225;rez-Garc&#237;a"
        "autores" => array:4 [
          0 => array:4 [
            "nombre" => "Mar&#237;a"
            "apellidos" => "Rojas-Feria"
            "email" => array:1 [
              0 => "mrojasferia@gmail.com"
            ]
            "referencia" => array:2 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">b</span>"
                "identificador" => "aff0010"
              ]
              1 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">&#42;</span>"
                "identificador" => "cor0005"
              ]
            ]
          ]
          1 => array:3 [
            "nombre" => "Miguel"
            "apellidos" => "Rodr&#237;guez-Fern&#225;ndez"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">a</span>"
                "identificador" => "aff0005"
              ]
            ]
          ]
          2 => array:3 [
            "nombre" => "Manuel"
            "apellidos" => "Castro-Fern&#225;ndez"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">b</span>"
                "identificador" => "aff0010"
              ]
            ]
          ]
          3 => array:3 [
            "nombre" => "Emilio"
            "apellidos" => "Su&#225;rez-Garc&#237;a"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">b</span>"
                "identificador" => "aff0010"
              ]
            ]
          ]
        ]
        "afiliaciones" => array:2 [
          0 => array:3 [
            "entidad" => "Department of Internal Medicine&#44; Valme University Hospital&#44; UGC Internal Medicine&#44; Servicio Andaluz de Salud&#44; Seville E-41014&#44; Spain"
            "etiqueta" => "a"
            "identificador" => "aff0005"
          ]
          1 => array:3 [
            "entidad" => "Department of Digestive Diseases&#44; Valme University Hospital&#44; UGC Digestive Diseases&#44; Servicio Andaluz de Salud&#44; Seville E-41014&#44; Spain"
            "etiqueta" => "b"
            "identificador" => "aff0010"
          ]
        ]
        "correspondencia" => array:1 [
          0 => array:3 [
            "identificador" => "cor0005"
            "etiqueta" => "&#8270;"
            "correspondencia" => "Corresponding author&#46;"
          ]
        ]
      ]
    ]
    "titulosAlternativos" => array:1 [
      "es" => array:1 [
        "titulo" => "Lesi&#243;n hep&#225;tica colest&#225;sica inducida por vedolizumab"
      ]
    ]
    "resumenGrafico" => array:2 [
      "original" => 0
      "multimedia" => array:7 [
        "identificador" => "fig0005"
        "etiqueta" => "Figure 1"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "gr1.jpeg"
            "Alto" => 1684
            "Ancho" => 2508
            "Tamanyo" => 150194
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">Temporal evolution of liver-associated enzymes in the course of VDZ treatment&#46;</p>"
        ]
      ]
    ]
    "textoCompleto" => "<span class="elsevierStyleSections"><p id="par0005" class="elsevierStylePara elsevierViewall">Vedolizumab &#40;VDZ&#41; is a monoclonal antibody that selectively targets &#945;4&#946;7 integrin&#44; approved to treat moderate-to-severe inflammatory bowel disease &#40;IBD&#41;&#46; It has a safety profile related to its mechanism of action&#44; characterized by a gut-selectivity&#46;<a class="elsevierStyleCrossRefs" href="#bib0030"><span class="elsevierStyleSup">1&#44;2</span></a> Pre-marketing data&#44; in an analysis that included over 2800 VDZ-exposed patients only showed a 0&#46;82&#37; of hepatobiliary events&#46;<a class="elsevierStyleCrossRef" href="#bib0035"><span class="elsevierStyleSup">2</span></a> No cases of cholestasis were reported&#46;</p><p id="par0010" class="elsevierStylePara elsevierViewall">In this report&#44; we describe the case of an 82-year-old man&#44; without toxic habits and with hypertension&#44; past hepatitis B&#44; prostatectomy for adenocarcinoma and Parkinson&#39;s disease&#46; He was diagnosed with severe ulcerative colitis &#40;UC&#41; and was treated with different therapies such as mesalazine&#44; steroids and infliximab &#40;IFX&#41;&#46; The latest one was discontinued because of secondary loss of response&#46; Two months later&#44; VDZ was started&#44; three doses of 300<span class="elsevierStyleHsp" style=""></span>mg intravenous infusions at weeks 0&#44; 2 and 6&#46;</p><p id="par0015" class="elsevierStylePara elsevierViewall">Laboratory analysis at the beginning of the treatment showed a normal hepatic profile&#46; Before the first maintenance session&#44; laboratory tests showed an anicteric cholestasis&#44; with high levels of Gamma-Glutamyl Transferase &#40;GGT&#41; and Alkaline Phosphatase &#40;ALP&#41; &#40;GGT 948<span class="elsevierStyleHsp" style=""></span>U&#47;L&#44; ALP 909<span class="elsevierStyleHsp" style=""></span>U&#47;L&#41;&#46; Aspartate aminotransferase &#40;AST&#41; was 132<span class="elsevierStyleHsp" style=""></span>U&#47;L and alanine aminotransferase &#40;ALT&#41; 169<span class="elsevierStyleHsp" style=""></span>U&#47;L&#46; The patient remained asymptomatic&#46; He denied any change in his usual medication&#46; Serological markers of autoimmunity were positive &#40;presence of antinuclear &#40;ANA&#41; and smooth muscle antibodies &#40;ASMA&#41; in a titre<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>1&#47;320&#41;&#46; Immunoglobulin levels&#44; other laboratory tests&#44; abdominal ultrasound and a nuclear colangioresonance were normal&#46; Cholestatic liver injury attributable to VDZ was assumed&#46; The Council for International Organizations of medical Sciences &#40;CIOMS&#41; scale<a class="elsevierStyleCrossRef" href="#bib0040"><span class="elsevierStyleSup">3</span></a> classified the event as probable &#40;score of 8&#41;&#44; according to its likelihood to be drug-induced liver injury &#40;DILI&#41;&#46; Liver biopsy was not considered because of the frailty of the patient&#46; The drug was withdrawn and ursodeoxycholic acid at a dosage of 15<span class="elsevierStyleHsp" style=""></span>mg&#47;kg for two weeks was recommended&#46;</p><p id="par0020" class="elsevierStylePara elsevierViewall">The patient received oral prednisone&#44; 50<span class="elsevierStyleHsp" style=""></span>mg&#47;day for two weeks&#44; that was tapered and maintained at 20<span class="elsevierStyleHsp" style=""></span>mg&#47;day for 12 weeks&#44; because of UC relapse&#46; Cholestasis lasted for 8 months &#40;<a class="elsevierStyleCrossRef" href="#fig0005">Fig&#46; 1</a>&#41;&#46; Serum enzymes remained normal&#44; ASMA became negative and ANA titre was 1&#47;160 after corticosteroid cessation&#46; No liver biochemical abnormalities have been observed after a follow-up of 2 years&#46;</p><elsevierMultimedia ident="fig0005"></elsevierMultimedia><p id="par0025" class="elsevierStylePara elsevierViewall">DILI classified by the criteria of the International Consensus Conference&#44; corresponded to a cholestatic pattern&#46; Previous studies described few cases of hepatocellular type of DILI that obliged to interrupt VDZ&#46; Our patient had a cholestatic liver injury&#44; which could be explained because of his advanced age&#44; as older patients are more prone to a cholestatic pattern of DILI&#46;<a class="elsevierStyleCrossRef" href="#bib0045"><span class="elsevierStyleSup">4</span></a> After a review of the published scientific literature&#44; we have found just a single case of cholestatic liver injury attributable to VDZ&#46;<a class="elsevierStyleCrossRef" href="#bib0050"><span class="elsevierStyleSup">5</span></a> It should be noted that in both cases&#44; DILI occurred after the induction therapy of VDZ&#46; Unlike our case&#44; it occurred in a young patient and it progressed to chronic liver injury despite prompt drug withdrawal and steroid treatment&#46;</p><p id="par0030" class="elsevierStylePara elsevierViewall">The main limitation of our case is the lack of a liver biopsy which was not considered because of the favorable outcome and the advanced age of the patient&#46; Moreover&#44; in suspected DILI cases it does not provide definitive diagnostic information in most instances&#46;<a class="elsevierStyleCrossRef" href="#bib0045"><span class="elsevierStyleSup">4</span></a> Our diagnostic was supported by the CIOMS scale<a class="elsevierStyleCrossRef" href="#bib0040"><span class="elsevierStyleSup">3</span></a> and the clinical evolution&#46; Although ANA and ASMA were found positive&#44; serologic markers of autoimmunity have also been described in DILI from other biological treatment&#44; as IFX&#46; Autoimmune hepatitis &#40;AIH&#41; and AIH-DILI&#44;<a class="elsevierStyleCrossRef" href="#bib0045"><span class="elsevierStyleSup">4</span></a> a particular phenotype of hepatotoxicity&#44; were not considered as alternative causes because rises in ALT and AST were mild&#46; Although potential autoimmune etiology can not be ruled out&#44; the history of exposure to the medication and the resolution of biochemical abnormalities without relapse&#44; support the diagnosis of DILI&#46;<a class="elsevierStyleCrossRef" href="#bib0045"><span class="elsevierStyleSup">4</span></a></p><p id="par0035" class="elsevierStylePara elsevierViewall">In conclusion&#44; although VDZ is a safe treatment&#44; monitoring hepatic enzymes during VDZ therapy should be recommended&#46;</p><span id="sec0005" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0005"><span class="elsevierStyleBold">Authors&#8217; contributions</span></span><p id="par0040" class="elsevierStylePara elsevierViewall">Rojas-Feria M&#46; treated the patient&#46; Rodr&#237;guez-Fern&#225;ndez M&#46; collected the patient&#39;s clinical data&#46; Rodr&#237;guez-Fern&#225;ndez M&#46; and Rojas-Feria M&#46; designed the report&#46; Rodr&#237;guez-Fern&#225;ndez M&#46;&#44; Rojas-Feria M&#46;&#44; Castro-Fern&#225;ndez M&#46; and Su&#225;rez-Garc&#237;a E&#46; wrote the paper&#46;</p></span><span id="sec0010" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0010"><span class="elsevierStyleBold">Informed consent statement</span></span><p id="par0045" class="elsevierStylePara elsevierViewall">Consent was obtained from relatives of the patient for publication of this report&#46;</p></span><span id="sec0015" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0015"><span class="elsevierStyleBold">Financial support</span></span><p id="par0050" class="elsevierStylePara elsevierViewall">None&#46;</p></span><span id="sec0020" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0020"><span class="elsevierStyleBold">Conflicts of interest</span></span><p id="par0055" class="elsevierStylePara elsevierViewall">The authors declare that they have no conflicts of interest&#46;</p></span></span>"
    "textoCompletoSecciones" => array:1 [
      "secciones" => array:5 [
        0 => array:2 [
          "identificador" => "sec0005"
          "titulo" => "Authors&#8217; contributions"
        ]
        1 => array:2 [
          "identificador" => "sec0010"
          "titulo" => "Informed consent statement"
        ]
        2 => array:2 [
          "identificador" => "sec0015"
          "titulo" => "Financial support"
        ]
        3 => array:2 [
          "identificador" => "sec0020"
          "titulo" => "Conflicts of interest"
        ]
        4 => array:1 [
          "titulo" => "References"
        ]
      ]
    ]
    "pdfFichero" => "main.pdf"
    "tienePdf" => true
    "multimedia" => array:1 [
      0 => array:7 [
        "identificador" => "fig0005"
        "etiqueta" => "Figure 1"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "gr1.jpeg"
            "Alto" => 1684
            "Ancho" => 2508
            "Tamanyo" => 150194
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">Temporal evolution of liver-associated enzymes in the course of VDZ treatment&#46;</p>"
        ]
      ]
    ]
    "bibliografia" => array:2 [
      "titulo" => "References"
      "seccion" => array:1 [
        0 => array:2 [
          "identificador" => "bibs0015"
          "bibliografiaReferencia" => array:5 [
            0 => array:3 [
              "identificador" => "bib0030"
              "etiqueta" => "1"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "The safety of vedolizumab for ulcerative colitis and Crohn&#39;s disease"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "J&#46;F&#46; Colombel"
                            1 => "B&#46;E&#46; Sands"
                            2 => "P&#46; Rutgeerts"
                            3 => "W&#46; Sandborn"
                            4 => "S&#46; Danese"
                            5 => "G&#46; D&#8217;Haens"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1136/gutjnl-2015-311079"
                      "Revista" => array:6 [
                        "tituloSerie" => "Gut"
                        "fecha" => "2017"
                        "volumen" => "66"
                        "paginaInicial" => "839"
                        "paginaFinal" => "851"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/26893500"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            1 => array:3 [
              "identificador" => "bib0035"
              "etiqueta" => "2"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "The safety profile of vedolizumab in ulcerative colitis and Crohn&#39;s disease&#58; 4 years of global post-marketing data"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:4 [
                            0 => "R&#46;D&#46; Cohen"
                            1 => "F&#46; Bhayat"
                            2 => "A&#46; Blake"
                            3 => "S&#46; Travis"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1093/ecco-jcc/jjz137"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Crohns Colitis"
                        "fecha" => "2020"
                        "volumen" => "14"
                        "paginaInicial" => "192"
                        "paginaFinal" => "204"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/31504340"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            2 => array:3 [
              "identificador" => "bib0040"
              "etiqueta" => "3"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Causality assessment of adverse reactions to drugs &#8211; I&#46; A novel method based on the conclusions of international consensus meetings&#58; application to drug-induced liver injuries"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:2 [
                            0 => "G&#46; Danan"
                            1 => "C&#46; Benichou"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/0895-4356(93)90101-6"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Clin Epidemiol"
                        "fecha" => "1993"
                        "volumen" => "46"
                        "paginaInicial" => "1323"
                        "paginaFinal" => "1330"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/8229110"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            3 => array:3 [
              "identificador" => "bib0045"
              "etiqueta" => "4"
              "referencia" => array:1 [
                0 => array:1 [
                  "referenciaCompleta" => "European Association for the Study of the Liver EASL&#46; Clinical practice guidelines&#58; drug-induced liver injury&#46; J Hepatol&#46; 2019&#59;70&#58;1222&#8211;61&#46; <a target="_blank" href="doi:10.1016/j.jhep.2019.02.014">doi&#58;10&#46;1016&#47;j&#46;jhep&#46;2019&#46;02&#46;014</a>&#46; Epub 2019 Mar 27&#46; PubMed PMID&#58; 30926241&#46;"
                ]
              ]
            ]
            4 => array:3 [
              "identificador" => "bib0050"
              "etiqueta" => "5"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Chronic cholestatic liver injury attributable to vedolizumab"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:3 [
                            0 => "J&#46;G&#46; Stine"
                            1 => "J&#46; Wang"
                            2 => "B&#46;W&#46; Behm"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.14218/JCTH.2016.00018"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Clin Transl Hepatol"
                        "fecha" => "2016"
                        "volumen" => "4"
                        "paginaInicial" => "277"
                        "paginaFinal" => "280"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/27777897"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
          ]
        ]
      ]
    ]
  ]
  "idiomaDefecto" => "en"
  "url" => "/02105705/0000004500000001/v2_202201010823/S0210570520304428/v2_202201010823/en/main.assets"
  "Apartado" => array:4 [
    "identificador" => "9010"
    "tipo" => "SECCION"
    "es" => array:2 [
      "titulo" => "Cartas al Director"
      "idiomaDefecto" => true
    ]
    "idiomaDefecto" => "es"
  ]
  "PDF" => "https://static.elsevier.es/multimedia/02105705/0000004500000001/v2_202201010823/S0210570520304428/v2_202201010823/en/main.pdf?idApp=UINPBA00004N&text.app=https://www.elsevier.es/"
  "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0210570520304428?idApp=UINPBA00004N"
]
Article information
ISSN: 02105705
Original language: English
The statistics are updated each day
Year/Month Html Pdf Total
2024 November 3 2 5
2024 October 30 13 43
2024 September 54 5 59
2024 August 28 8 36
2024 July 37 16 53
2024 June 38 12 50
2024 May 30 11 41
2024 April 35 14 49
2024 March 45 13 58
2024 February 41 9 50
2024 January 28 2 30
2023 December 10 0 10
2023 November 9 0 9
2023 October 18 0 18
2023 September 10 0 10
2023 August 12 0 12
2023 July 13 0 13
2023 June 13 2 15
2023 May 2 0 2
2023 April 4 1 5
2023 March 5 5 10
2023 February 5 4 9
2023 January 9 7 16
2022 December 7 8 15
2022 November 5 5 10
2022 October 5 5 10
2022 September 7 6 13
2022 August 7 11 18
2022 July 1 2 3
2022 June 2 4 6
2022 May 1 0 1
2022 April 5 0 5
2022 March 5 1 6
2022 February 27 7 34
2022 January 14 12 26
2021 December 7 4 11
2020 December 0 2 2
Show all

Follow this link to access the full text of the article

es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos